Clinical Trials
16
Active:2
Completed:13
Trial Phases
2 Phases
Phase 3:3
Not Applicable:12
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Not Applicable
12 (80.0%)Phase 3
3 (20.0%)An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.
Not Applicable
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT06486948
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
Not Applicable
Completed
- Conditions
- Atopic DermatitisPsoriasis
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06275659
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
Not Applicable
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT06136936
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
Not Applicable
Completed
- Conditions
- Lung CancerBreast CancerMultiple Sclerosis
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT06136923
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
Phase 3
Active, not recruiting
- Conditions
- SchizophreniaNegative Symptoms in Schizophrenia
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT06067984
- Locations
- 🇺🇸
Click Therapeutics, New York City, New York, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found